OmniAb, Inc. Warrant

VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The com...

AI is transforming healthcare through innovative technologies like disease screening, genetic testing, antibody discovery, and drug development platforms, with several companies making significant technological advancements in medical AI applications.

VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.